for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,820.00GBp

Change

-18.00(-0.98%)

Volume

7,526,374

Today's Range

1,813.40

 - 

1,846.00

52 Week Range

1,429.80

 - 

1,851.15

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,838.00
Open
1,831.80
Volume
7,526,374
3M AVG Volume
131.80
Today's High
1,846.00
Today's Low
1,813.40
52 Week High
1,851.15
52 Week Low
1,429.80
Shares Out (MIL)
4,989.60
Market Cap (MIL)
91,708.78
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 GlaxoSmithKline PLC Earnings Release

Latest Developments

More

U.S. FDA Grants Priority Review To GSK's Multiple Myeloma Drug

U.S. FDA Grants Priority Review Of GSK's Belantamab Mafodotin For Patients With Relapsed Or Refractory Multiple Myeloma

Vectura Sees FY Rev, Adj. EBITDA At Least In Line With Its View

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Contact Info

G S K House, 980 Great West Road

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.54 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2016

27.9K

2017

30.2K

2018

30.8K

2019(E)

33.6K
EPS (GBp)

2016

102.400

2017

111.800

2018

119.400

2019(E)

122.872
Price To Earnings (TTM)
19.58
Price To Sales (TTM)
2.77
Price To Book (MRQ)
7.79
Price To Cash Flow (TTM)
11.00
Total Debt To Equity (MRQ)
280.74
LT Debt To Equity (MRQ)
210.95
Return on Investment (TTM)
11.20
Return on Equity (TTM)
7.30

Latest News

Latest News

GSK appeal against fine over 'pay-for-delay' drug deals faces EU rebuke

British drugmaker GlaxoSmithKline may have harmed competition with payments it made to generic drugmakers to delay the launch of cheap copies of an antidepressant, according to an adviser to the European Court of Justice.

GSK appeal against fine over 'pay-for-delay' drug deals faces EU rebuke

British drugmaker GlaxoSmithKline <GSK.L> may have harmed competition with payments it made to generic drugmakers to delay the launch of cheap copies of an antidepressant, according to an adviser to the European Court of Justice.

Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs

Drugmakers including Pfizer Inc <PFE.N>, GlaxoSmithKline PLC <GSK.L> and Sanofi SA <SASY.PA> are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.

U.S. FDA declines to approve GSK drugs division's long acting HIV injection

GlaxoSmithKline's HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection.

How a seven-month-old Supreme Court ruling revived a seven-year-old case against GSK

In December 2017, U.S. District Judge Cynthia Rufe of Philadelphia seemingly drove a stake through the heart of litigation by two employee healthcare funds suing GlaxoSmithKline over its marketing of the diabetes drug Avandia. The plans, which sued back in 2010, alleged...

Britain's GSK seeks U.S approval for rival to J&J's multiple myeloma drug

GlaxoSmithKline <GSK.L> said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson <JNJ.N> and Genmab's Darzalex.

GSK seeks FDA approval for investigational HIV treatment

GlaxoSmithKline Plc said on Thursday its HIV unit has submitted a new drug application to the U.S. Food and Drug Administration seeking approval for fostemsavir, an experimental treatment for HIV in adults.

GSK sees breakthrough in shingles vaccine output in 2024

GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.

GSK eyes 'step change' in shingles vaccine output in 2024

GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a "step change" in production.

Merck KGaA raises 2019 guidance after Versum takeover

German science and technology company Merck KGaA <MRCG.DE> raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials <VSM.N> in October.

GSK raises profit forecast after shingles vaccine sales boost

GlaxoSmithKline <GSK.L> on Wednesday raised its annual profit forecast for the second time this year as sales of its shingles vaccine beat expectations and older medicines, including HIV treatments, continued to sell well.

GSK lifts annual profit forecast after Q3 beat

GlaxoSmithKline Plc on Wednesday raised its annual profit forecast for the second time this year as soaring sales of its Shingles vaccine helped offset a hit from generic competition to its blockbuster asthma drug Advair.

GlaxoSmithKline starts late-stage trial for experimental antibiotic

GlaxoSmithKline Plc <GSK.L> said on Monday it has begun a late-stage study testing its experimental antibiotic in patients with urinary tract infections and gonorrhoea, a type of sexually transmitted infection.

GSK gets FDA nod for wider use of ovarian cancer drug Zejula

GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.

U.S. FDA okays wider use of GSK ovarian cancer drug

GlaxoSmithKline said on Wednesday U.S. regulators approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.

Timeline: Popular heartburn medicine Zantac pulled off store shelves

The U.S. Food and Drug Administration and international health authorities are investigating the safety of Zantac heartburn medicine, also sold generically as ranitidine, after finding a probable cancer-causing impurity in the drug.

GSK to sell two vaccines in $1.1 billion deal to focus on newer treatments

GlaxoSmithKline will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said on Monday, as it looks to bolster its push into the lucrative cancer drug market.

GSK to sell two travel vaccines to Danish biotech firm

GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).

GSK recalls popular heartburn drug Zantac globally after cancer scare

GlaxoSmithKline <GSK.L> on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug.

GSK recalls popular heartburn medicine Zantac - U.K. medicines watchdog

GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a "precautionary measure" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up